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Abstract
Background: Urinary albumin excretion is known to be independently associated with progression of renal and
cardiovascular disease. The aim of this study was to identify predictors for progression in albuminuria in the general
population.
Methods: Data were used of the first 4 screening rounds of a community-based prospective cohort study (PREVEND).
Included were 5,825 subjects that at baseline had no known renal disease or macroalbuminuria. Subjects were defined as
having progressive albuminuria when they belonged to the quintile of subjects with highest absolute increase in urinary
albumin excretion per year and a urinary albumin excretion during the last screening in which they participated of
$150 mg/24 h. Change in urinary albumin excretion per year was calculated as last available urinary albumin excretion
minus baseline UAE divided by follow-up time.
Results: During 9.3 years follow-up 132 subjects had progressive albuminuria. These subjects were significantly older, more
often of male gender and had a worse cardiovascular risk profile. In a multivariable model, testing baseline values,
significant predictors of progressive albuminuria were male gender (OR 2.23; p,0.001), age (OR 1.03; p,0.001), BMI (OR
1.06; p = 0.02) and baseline albuminuria (OR 5.71; p,0.001). Based on these findings a risk score was made to estimate a
subject’s risk for progressive albuminuria.
Conclusion: A high baseline albuminuria is by far the most important predictor of progressive albuminuria. Thus, screening
for baseline albuminuria will be more important than screening for cardiovascular risk factors in order to identify subjects at
risk for progressive albuminuria.
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Introduction
Chronic kidney disease (CKD) is defined by an impaired
glomerular filtration rate (GFR) or an increased urinary albumin
excretion (UAE).[1] Numerous studies have shown that an impaired
GFR is associated with a poor cardiovascular [2,3], but also with a
poor renal outcome [4]. Many studies evaluated which factors are
associated with progressive GFR decline. Prediction models have
been developed to estimate the risk of an individual to develop end-
stage renal disease. Some of these predictionmodels were developed
for high risk populations, such as people with known underlying
cardiovascular disease [5], or for specific kidney diseases, such as IgA
nephropathy [6] and diabetic nephropathy [7]. We recently
published a risk score for future eGFR loss in community dwelling
subjects using demographic data, aswell as data that can be obtained
in screening programs [8].
It has been shown that not only GFR, but also a higher UAE is
associated with a worse cardiovascular and renal prognosis [2,4,9]
and that a rise in UAE is particularly associated with risk of poor
cardiovascular or renal outcome [10–12]. It is therefore of interest
to develop also prediction models to estimate the risk of an
individual to develop progressive UAE. As yet such risk models are
lacking. Furthermore, information on risk factors for an increase in
albuminuria are known in patients with diabetes mellitus.
However, such information is not available for the general,
predominantly non-diabetic population.
In the present study we therefore investigated which factors are
associated with progressive albuminuria. Not only baseline
characteristics were taken into account, but also short-term
changes in parameters like blood glucose and systolic blood
pressure. Using the identified risk factors a model was designed to
predict who will develop a progressive increase in albuminuria, in
analogy to the model we recently designed to predict for each
individual the risk to develop progressive eGFR loss [8].
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Patients and Methods
Study design and population
This study was conducted using data of subjects participating in
the Prevention of REnal and Vascular ENd-stage Disease
(PREVEND) study. This prospective, population based cohort
study investigates the natural course of UAE and its relation with
renal and cardiovascular disease. Details of the study protocol
have been published elsewhere [13,14]. In summary, all inhab-
itants of the city of Groningen aged 28–75 years were sent a
questionnaire and a vial to collect a first-morning-void urine
sample. Of these subjects, 40,856 responded (47.8%) and returned
this vial to a central laboratory for urinary albumin assessment.
From these 40,856 subjects the PREVEND cohort was selected
with the aim to create a cohort enriched for the presence of
albuminuria. After exclusion of subjects with type 1 diabetes
mellitus (defined as subjects requiring the use of insulin) and
pregnant females (defined by self report), all subjects with a urinary
albumin concentration of .10 mg/L (n= 7,768) were invited for
the first screening round, and 6,000 participated. Furthermore, a
randomly selected control group with a urinary albumin
concentration of ,10 mg/L (n= 3,394) was also invited, and
2,592 participated. These 8,592 subjects constitute the actual
PREVEND cohort and were asked to collect 2 consecutive 24-
hour urine samples (baseline screening). The first screening round
was completed in 1997–98 by 8,592 participants. Thereafter,
participants were invited to visit the outpatient clinic for a medical
examination at approximately 3-year intervals. The PREVEND
study was approved by the medical ethics committee of the
University Medical Center Groningen and conducted in accor-
dance with the guidelines of the Declaration of Helsinki. All
participants gave written informed consent.
For the present study, we excluded subjects with at baseline
known renal disease (N=20) or macroalbuminuria (N= 134), and
subjects in whom no data on untreated UAE value was available.
At baseline there were: N= 112 (1.9%) participants with CKD
stage 1 (eGFR.90 ml/min/1.73 m2 and UAE 30-300 mg/24 h);
N= 395 (6.8%) participants with CKD stage 2 (eGFR 60-89 ml/
min/1.73 m2 and UAE 30-300 mg/24 h); N= 228 (3.9%) partic-
ipants with CKD stage 3 (GFR 30–59 mL/min/1.73 m2); N= 26
Figure 1. Median (IQR) urinary albumin excretion (UAE) of subjects meeting the definition of progressive albuminuria (open bars)
and subjects without progressive albuminuria (dark bars) during the various screening rounds of the PREVEND cohort. The upper
panel shows data of all participants, whereas the lower panel shows data of only participants with follow-up until the last screening. Abbreviations: N
denotes the number of participants.
doi:10.1371/journal.pone.0061119.g001
Prediction of Progression in Albuminuria
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e61119
(0.4%) participants with CKD stage 4 (GFR 15–29 mL/min/
1.73 m2). There were no subjects with stage CKD stage 5 (GFR
,15 mL/min/1.73 m2).
Measurements
During each screening round participants filled out a question-
naire on demographics, cardiovascular and renal disease history,
smoking status and the use of oral blood pressure, glucose and lipid
lowering drugs. Information on drug use was completed with data
from community pharmacies [15] (www.iadb.nl). Anthropome-
trical measurements were performed, and fasting blood samples
were taken. Blood pressure was measured in supine position, every
minute, for 10 and 8 min, with an automatic device (Dinamap XL
Model 9300; Johnson-Johnson Medical, Tampa, FL). Blood
pressure is given as the mean of the last two recordings of both
visits. Concentrations of total cholesterol and plasma glucose were
measured using standard methods. Serum creatinine was mea-
sured by dry chemistry (Eastman Kodak, Rochester, New York,
USA), with intra-assay coefficient of variation of 0.9% and
interassay coefficient of variation of 2.9%. Participants were
instructed not to collect urine in case of infectious diseases and to
refrain from intensive physical activity during the collection
period. Urinary albumin concentration was measured in these
fresh urine samples by nephelometry with a threshold of 2.3 mg/L
and intra- and interassay coefficients of variation of 2.2 and 2.6%,
respectively (BNII; Dade Behring Diagnostic, Marburg, Ger-
many). UAE is given as the mean of the two 24-h urine collections.
Definitions
Known kidney disease was defined as present or past kidney
disease requiring dialysis. Participants were considered as smoking
when they stated to have smoked in the year previous to the
screening. A cardiovascular disease history was defined as self
reported myocardial infarction, percutaneous transluminal coro-
nary angioplasty, coronary artery bypass graft or cerebrovascular
accident. Body mass index was calculated as the ratio between
weight and the square of height. Hypertension was defined as
systolic blood pressure $140 mmHg or diastolic blood pressure
$90 mmHg or use of blood pressure lowering medication
according to self report or pharmacy data (JNC-7 definition).
Known hypertension was defined as use of blood pressure
lowering medication. Hyperlipidemia was defined as a cholesterol
level .5.0 mmol/L when a history of cardiovascular disease was
present, a cholesterol level of .6.5 mmol/L when a history of
cardiovascular disease was absent, or use of lipid lowering drugs.
Known hyperlipidemia was defined as use of lipid lowering
medication. Diabetes mellitus was defined as a fasting glucose level
of .7.0 mmol/L, a non-fasting glucose level of .11.1 mmol/L or
use of glucose lowering medication (ADA definition).[16] Known
diabetes was defined as use of glucose lowering medication. eGFR
was estimated using the Modification of Diet in Renal Disease
(MDRD) study equation, taking into account gender, age, race
and serum creatinine. Short-term change in potential risk factors
was defined as the difference between values obtained at the
second minus the first screening round (median follow-up of
4.2 years).
Subjects were defined as having progressive albuminuria when
they belonged to the quintile of subjects with highest absolute
Table 1. Baseline characteristics.
Progressive albuminuria No progressive albuminuria p-value
Number 132 5693 –
Male (%) 75.0 48.3 ,0.001
Age (yrs) 57.8611.4 48.1611.9 ,0.001
Smoking (%) 40.9 36.1 0.25
History of CVD (%) 12.1 3.7 ,0.001
BMI (kg/m2) 28.164.3 25.663.9 ,0.001
SBP (mmHg) 138.2620.7 125.1617.4 ,0.001
DBP (mmHg) 77.8 69.4 72.468.9 ,0.001
Known hypertension (%) 40.0 13.8 ,0.001
Use of ACEi or ARB (%) 15.4 4.9 ,0.001
Hypertension (%) 61.4 13.8 ,0.001
Cholesterol (mmol/L) 5.761.1 5.561.1 0.09
Known hyperlipidemia (%) 17.4 5.8 ,0.001
Hyperlipidemia (%) 43.2 24.1 ,0.001
Glucose (mmol/L) 5.161.0 4.760.8 0.002
Known diabetes (%) 2.3 1.2 0.22
Diabetes (%) 2.3 1.8 0.69
CRP (mg/L) 1.6[0.9–4.0] 1.1[0.5–2.6] ,0.001
Serum creatinine (mmol/L) 94.6624.6 82.8613.5 ,0.001
eGFR (mL/min/1.73 m2) – 81.4613.6 ,0.001
UAE (mg/24 h) 67.4[35.3-116.4] 8.4[6.1–13.5] ,0.001
Abbreviations: CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACEi, angiotensin converting enzyme
inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion.
doi:10.1371/journal.pone.0061119.t001
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increase in UAE per year AND a UAE during the last screening in
which they participated of $150 mg/24 h. Change in UAE per
year was calculated as last available UAE minus baseline UAE
divided by follow-up time. Of note, in case participants started
after the baseline screening medication known to influence the
natural course of albuminuria (i.e. blood pressure, glucose or lipid
lowering drugs) the last available UAE value before start of such
medication was used for analyses. When subjects were already
using such medication during the baseline screening, these subjects
were eligible.
Statistical analysis
All calculations were performed with SPSS version 18.0
software. Continuous data are reported as mean 6SD. In case
of skewed distribution the median with interquartile range are
presented. Differences between the two cohorts for continuous
data were tested by Student’s t-test or a Mann–Whitney U test in
case of skewed distribution. Differences between groups for
proportions were tested with a chi-square test.
Model development
As possible predictors for progressive albuminuria we used
baseline parameters, that have been suggested in literature to be
renal risk factors: age, gender, cardiovascular disease history,
smoking, BMI, systolic blood pressure, use of ACE inhibitor/
Angiotensin Receptor Blocker (ACEi/ARB), known hypertension,
total plasma cholesterol, known hyperlipidemia, glucose, known
diabetes, eGFR and UAE. First, we analyzed univariable
associations between these predictors and progressive albuminuria
using logistic regression analysis. Second, a multivariable model
was built using backward selection. Only variables having a p-
value ,0.2 in univariable analysis were included in the
multivariable model (model 1). Values of UAE were logarithmi-
cally transformed to fulfil the requirement of linearity of the logit.
Given the definition of progressive albuminuria it could be
expected that baseline albuminuria itself will to be a strong
predictor. Therefore also a multivariable model was made
excluding baseline albuminuria (model 2). Subsequently, we
analysed the association of short-term changes in renal risk factors
with progressive albuminuria when added to models 1 and 2
(models 3 and 4, respectively). Model 1 was chosen as final
regression model, and tested for possible significant interactions
(all possible ones based on variables in model 1) and non-linear
associations between continuous predictors and progression in
albuminuria by adding quadratic terms. A variable was considered
to be statistically significantly associated with progression in
albuminuria when p,0.05. Lastly, based on model 1, a score chart
for prediction of progressive albuminuria was developed.
Model validation
The performance of the final model was evaluated by analysis of
the area under the Receiver Operating Characteristic (ROC)
curve. The internal validity of the prediction model was evaluated
by bootstrapping.[17] Two hundred samples of equal size were
drawn at random and with replacement from the complete
dataset. In these bootstrap samples the coefficients of the final
regression model were estimated and tested in the original sample.
The slope index (differences between the coefficients in the
original sample and bootstrap samples) was used as a shrinkage
method by multiplying coefficients with the slope index to correct
for ‘optimism’.
Prediction of an individual subject’s risk
A prediction model was developed based on the regression
coefficients in the final regression model. With this prediction rule
the probability of having progressive albuminuria after a follow-up
period of 9.3 years was estimated for each individual. The general
equation for estimating the probability (P) of having progressive
albuminuria is:
P~1=(1ze({lp))
The linear predictor (l p) consists of the regression coefficients
estimated in the final model, multiplied by the values of each
predictor for each patient. To facilitate calculation of an individual
subject’s risk in clinical practice analyses were also performed with
the predictors of the final prediction model subdivided into
clinically meaningful categories. With this model a numerical score
chart was derived, by rounding up the estimates of the
corresponding regression parameters obtained from the model.
The performance of this model was also evaluated by analysis of
area under the ROC curve. The diagnostic characteristics of this
model in terms of sensitivity, specificity, positive predictive value
and negative predictive value were calculated. All analyses were
performed with SPSS version 18.0 software, except bootstrapping,
which was performed in R version 2.13.0 for Windows.
Sensitivity analyses
Various sensitivity analyses were performed. First, we used the
CKD-EPI equation instead of the MDRD equation to estimate
Table 2. Results of univariable logistic regression analyses
exploring subject characteristics associated with progressive
albuminuria.
OR 95% CI p-value
Age (yr) 1.07 1.05–1.08 ,0.001
Male gender (vs. female) 3.21 2.16–4.77 ,0.001
Smoking (y/n) 1.23 0.86–1.74 0.25
Cardiovascular disease history (y/n) 3.55 2.07–6.09 ,0.001
BMI (kg/m2) 1.12 1.09–1.16 ,0.001
SBP (mmHg) 1.03 1.03–1.04 ,0.001
Known hypertension (y/n) 3.25 2.18-4.85 ,0.001
ACEi/ARB (y/n) 3.51 2.09–5.90 ,0.001
Glucose (mmol/L) 1.42 1.24–1.62 ,0.001
Known diabetes (y/n) 1.89 0.59–6.08 0.29
Total cholesterol (mmol/L) 1.15 0.98–1.34 0.09
Known hyperlipidemia (y/n) 3.40 2.14–5.41 ,0.001
CRP (mg/L) 1.02 0.99–1.05 0.09
Baseline eGFR (mL/min/1.73 m2) 0.97 0.95–0.98 ,0.001
UAE (mg/24 h), ln-transformed 6.34 5.22–7.71 ,0.001
Change in SBP (mmHg) 1.01 0.99–1.03 0.07
Change in cholesterol (mmol/L) 0.94 0.75–1.18 0.57
Change in BMI (kg/m2) 0.99 0.88–1.10 0.79
Change in glucose (mmol/L) 1.23 1.07–1.40 0.003
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; ACEi,
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker;
eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; OR,
odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0061119.t002
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GFR. Second, we used a different definition for progressive
albuminuria: an increase in UAE category (normoalbuminuria
defined as ,30 mg/24 h; microalbuminuria defined as 30-
300 mg/24 h and macroalbuminuria defined as .300 mg/24 h)
AND doubling of UAE from baseline till last follow-up. Third, we
performed a sensitivity analysis with the albumin to creatinine
ratio instead of the UAE for defining progression in albuminuria.
Finally, the PREVEND cohort was enriched for subjects with
higher UAE to acquire sufficient subjects with microalbuminuria.
Therefore design-based analyses were performed, which takes into
account this study design and allow to draw conclusions that are
valid for the general population.
Results
From the 8.592 subjects of the PREVEND cohort, we excluded
154 subjects with at baseline known renal disease or macroalbu-
minuria, and 2613 subjects in whom no follow-up data on
untreated UAE was available (1687 subjects with no UAE
measurement at follow-up and 926 subjects who started between
the baseline and the second screening treatment known to
influence the natural course of albuminuria). The present study
includes therefore 5,825 subjects. In these subjects median follow-
up was 9.3 years (minimum of 3.6 years and maximum of
11.3 years), and 132 subjects met our definition of progressive
UAE. Figure 1 shows median UAE values of these subjects during
the 4 screening rounds. Seventy seven participants were defined to
have progressive UAE based on data obtained at baseline (first)
and the last (fourth) screening round. Thirty one participants were
defined as such based on data obtained at baseline and the third
screening round (no data available at the fourth screening round,
or having started blood pressure, glucose or lipid lowering drugs
between the third and fourth screening round), and 24 participants
based on data obtained at baseline and the second screening round
(no data available at the third screening round, or having started
blood pressure, glucose or lipid lowering drugs between the second
and third screening round). In line with our definition UAE
increased gradually during follow-up in these subjects, whereas in
other subjects albuminuria remained fairly stable.
Table 1 shows the baseline characteristics of the 5,825 subjects
included in this analysis, subdivided according progressive UAE
Table 3. Results of the multivariable logistic regression analyses exploring subject’s characteristics associated with progressive
albuminuria.
Model 1 Model 2 Model 3 Model 4
R2 0.41 R2 0.14 R2 0.42 R2 0.15
OR (95% CI) p-value Wald OR (95% CI) p-value Wald OR (95% CI) p-value Wald OR (95% CI) p-value Wald
Male (vs. female) 2.23 (1.02–
1.05)
0.001 11.9 3.43 (2.24–5.25) ,0.001 32.3 2.26 (1.43–
3.58)
,0.001 12.2 3.45 (2.23–
5.33)
,0.001 31.2
Age (yrs) 1.03 (1.02–
1.05)
,0.001 13.7 1.04 (1.02–1.06) ,0.001 16.4 1.03 (1.02–
1.05)
,0.001 13.1 1.03 (1.01–
1.05)
0.004 8.2
Smoking (y/n)
History of CVD
Body Mass Index (kg/m2) 1.06 (1.01–
1.11)
0.02 5.6 1.11 (1.06-1.16) ,0.001 22.5 1.06 (1.01–
1.12)
0.01 6.0 1.10 (1.05–
1.15)
,0.001 18.1
SBP (mmHg) 1.01 (1.00–1.02) 0.04 4.1 1.01 (1.00–
1.03)
0.02 5.7
Known hypertension (y/n) 1.69 (1.10–
2.59)
0.02 5.8
Use of ACEi or ARB (y/n)
Cholesterol (mmol/L)
Known hyperlipidemia (y/n) 1.80 (1.11–2.91) 0.02 5.7
Glucose (mmol/L)
Known diabetes (y/n)
CRP (mg/L)
eGFR (mL/min/1.73m2) 0.98 (0.97–0.99) 0.01 6.7 0.98 (0.96–-
0.99)
0.005 8.1
UAE, ln-transformed 5.71 (4.64–
7.02)
,0.001 273.3 NA NA NA 5.78 (4.70–
7.11)
,0.001 275.3 NA NA NA
Change in BMI (kg/m2) NA NA NA NA NA NA
Change in glucose (mmol/L) NA NA NA NA NA NA 1.17 (1.03–
1.34)
0.02 5.8
Change in SBP (mmHg) NA NA NA NA NA NA 1.02 (1.01–
1.03)
0.006 7.4 1.02 (1.00–
1.03)
0.01 6.5
Change in cholesterol
(mmol/L)
NA NA NA NA NA NA
Abbreviations: CVD, cardiovascular disease; SBP, systolic blood pressure; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR,
estimated glomerular filtration rate; UAE, urinary albumin excretion; BMI, body mass index; OR, odds ratio; NA, not applicable.
doi:10.1371/journal.pone.0061119.t003
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status. The subjects who met the definition of having progressive
UAE were at baseline significantly older (57.8 vs. 48.1 years),
predominantly male (75.0%) and had a worse cardiovascular risk
profile (e.g. higher BMI, systolic blood pressure, diastolic blood
pressure and glucose).
Model development
In univariable logistic regression analyses age, male gender,
cardiovascular disease history, BMI, systolic blood pressure,
known hypertension, use of ACEi/ARB, glucose, total cholesterol,
known hyperlipidemia, and UAE at baseline were all positively
associated with progressive UAE, whereas eGFR showed a
negative association with progressive albuminuria. Changes in
systolic blood pressure and in glucose of baseline to second
screening were also associated with progressive albuminuria
(Table 2).
Table 3 presents the various multivariable models. Odds ratios,
p-values and Wald-statistics are only shown for variables that, after
backward selection, contributed to the model with a p,0.05. In
model 1, only including baseline covariates, male gender, age,
BMI and baseline UAE were associated with progressive
albuminuria. In model 2, the model with similar baseline
covariates but baseline UAE deleted from the model, the same
covariates as in model 1 were associated with progressive
albuminuria, and in addition it was found that systolic blood
pressure, eGFR and known hyperlipidemia were significantly
associated with progressive albuminuria. Models 3 and 4 are
similar to models 1 and 2, respectively, but include in addition
changes in covariates from baseline to second screening. Model 3
showed similar results as model 1, but now also an increase in
systolic blood pressure was associated with progressive albumin-
uria. When excluding UAE, model 4 shows results essentially
similar to model 2, whereas in addition an increase in glucose and
an increase in systolic blood pressure were associated with
progressive albuminuria. Of note, there were no interaction terms
between variables that remained in model 1, which showed a
significant association with progressive albuminuria.
Model validation
The multivariable regression coefficients of our final model
(Table 3, model 1) were additionally multiplied with the shrinkage
factor (0.99) that was obtained after bootstrapping, to correct for
‘optimism’. Based on these optimism corrected coefficients of the
multivariable logistic regression model presented in Table 3, the
prediction rule as given in equation 1 was constructed. When
making a ROC curve of model 1, our final model, the area under
the ROC curve was 0.94 [95%CI 0.92 to 0.96], indicating that the
discrimination of the model is high.
P~1=1ze{12:9z0:032(age)z1:742( ln UAE)z0:056(BMI)z0:800(gender)
Equation 1 is the Prediction rule based on the optimism
corrected coefficients of the multivariable logistic regression
model. In Equation 1 age is entered in years, gender as being
male (1) or female (0); body mass index as kg/m2 and albuminuria
as mg/24 h.
Prediction of an individual subject’s risk
Subsequently, for clinical use a model was built with the
variables that significantly contributed to the final model (model 1,
Table 3) subdivided into clinically meaningful categories. Results
are given in Table 4, which shows the numbers of subjects per
covariate, subdivided into meaningful categories and the odds
ratio’s with the lowest category as reference. A higher baseline
UAE was most markedly associated with a higher risk to develop
progressive albuminuria. Having an UAE of 15–30 mg/24 h
compared to ,15 mg/24 h had a greater odds ratio than being
.70 years of age, male, or being obese. The importance of
baseline UAE to predict progressive albuminuria is also reflected
by the R-square of the full model, which differ between 0.41 when
baseline UAE was included and 0.14 when baseline UAE was
excluded.
Table 4. Results of the univariable and multivariable logistic regression analyses for progressive albuminuria.
Variable N (total) N (progressors) OR (univariable) (95% CI) OR (multivariable) (95% CI)
Age (yrs)
,50 (ref) 3448 42 (1.2%) 1.00 1.00
50–70 2089 71 (3.4%) 2.85 (1.94–4.20) 1.20 (0.77–1.88)
.70 288 19 (6.6%) 5.73 (3.29–9.99) 1.74 (0.91–3.30)
Gender
Male 2851 99 (3.5%) 3.21 (2.16–4.77) 2.23 (1.43-3.47)
BMI (kg/m2)
,18.5 40 0 (0%) 0.00 (2) 0.00 (2)
18.5–24 (ref) 2678 29 (1.1%) 1.00 1.00
25–29 2300 67 (2.9%) 2.74 (1.77–4.25) 1.64 (1.01-2.68)
.30 744 36 (4.8%) 4.65 (2.83–7.63) 2.02 (1.16-3.51)
UAE (mg/24 h)
,15 (ref) 4489 15 (0.3%) 1.00 1.00
15–29 769 13 (1.7%) 5.13 (2.43–10.8) 4.29 (2.02–9.11)
30–149 520 81 (15.6%) 55.0 (31.4–96.3) 41.7 (23.4–74.3)
150–300 47 23 (48.9%) 285.8 (133.1–613.8) 233.0 (105.9–512.4)
Abbreviations: BMI, body mass index; UAE, urinary albumin excretion; SBP, systolic blood pressure; N, number; OR, odds ratio.
doi:10.1371/journal.pone.0061119.t004
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The regression coefficients of this model were also corrected for
‘optimism’ by multiplying the coefficients of the original model by
the shrinkage factor (shrinkage = 0.98). Based on the coefficients of
the model in Table 4 a score chart was derived that is presented in
Table 5. It shows that the predominant covariate to predict
progressive albuminuria is baseline albuminuria. For instance, a
woman of ,50 years with a BMI ,25 kg/m2, but with a baseline
UAE of 30–150 mg/24 h scores 17 points, which is more than the
10 points that are scored by an obese man of .70 years, but with
a baseline UAE,15 mg/24 h. The area under the ROC curve
was 0.92 [95%CI 0.89 to 0.94], indicating that the discrimination
of the model is high. The diagnostic characteristics of the model
are given in Table 6.
Sensitivity analyses
Various sensitivity analyses were performed. First, we used the
CKD-EPI equation [18] instead of the MDRD equation to
estimate GFR. It showed that model 1, which we adopted to use as
our final model, presents results similar to our primary analyses
(Table S1). Second, we used a different definition for progressive
albuminuria: an increase in UAE category and doubling of UAE
from baseline till last follow-up. By using this definition 362
subjects were defined as having progressive albuminuria. Their
baseline characteristics are shown in Table S2. Baseline median
UAE level and albuminuria during follow-up (16.3 [10.7–
23.0] mg/24 h) and 56.4 (40.8-106.5), respectively) were less
compared to the value obtained in the 132 progressors that met
the definition of progressive albuminuria adopted for the primary
analyses. Like the final model of the primary analyses, the final
model of this sensitivity analysis showed that baseline UAE, age,
male gender, BMI and known hyperlipidemia were significantly
associated with progressive albuminuria (Table S3). Third, when
performing a sensitivity analysis defining progressive albuminuria
using albumin to creatinine ratio instead of urinary albumin
excretion 104 participants were defined as having progressive
UAE. Only minor differences were observed in the multivariable
regression models when compared to the primary analyses (eGFR
instead of age included in the final model, Table S4. Finally,
because of the enrichment of the PREVEND study for higher
levels of albuminuria we performed weighted analyses. Again
similar results were obtained as in the primary analyses, the only
difference being that now also known hypertension and use of
ACE inhibitors/ angiotensin receptor blockers were significant
covariates.
Discussion
In the present study we show that in a community-based cohort
a higher baseline UAE is the most important variable that predicts
whether an individual will develop progressive albuminuria during
follow-up. Of all other variables taken into account only higher
age, male gender and higher BMI were predictors for the risk to
develop progressive albuminuria, but not higher systolic blood
pressure and higher plasma glucose. Systolic blood pressure only
became a significant predictor when we eliminated baseline UAE
from the multivariable model. When we, in addition, took into
account also changes in baseline covariates, it appeared that also
changes in systolic blood pressure and plasma glucose were
predictors for progressive albuminuria. Finally, we found that
when building a score chart to predict risk for progressive
albuminuria, the risk associated with a baseline UAE in the range
of microalbuminuria by far outweighed the risk associated with
male gender, a higher baseline age or BMI.
Thus far, most studies investigating factors that are associated
with progression of UAE have been performed in subjects with
type 1 or type 2 diabetes mellitus [19–22] Baseline UAE, male
gender, blood pressure and HbA1c concentration were indepen-
dently associated with progression of albuminuria in a cohort of
Caucasian subjects with type 1 diabetes [21]. Similarly, in a
Japanese cohort with subjects with type 2 diabetes under tight
glycemic and blood pressure control, baseline UAE and systolic
blood pressure were positively correlated with progression of UAE
[22]. Only few studies investigated predictors of progressive
albuminuria in non-diabetic populations. A recent analysis of the
ONTARGET study that was performed in subjects at high risk for
vascular disease (of which about two third was non-diabetic)
showed with multivariable regression analysis, that an increase in
systolic blood pressure and in heart rate and a fall in serum
creatinine were associated with changes in UAE [11]. Another
study performed in the Framingham Offspring Cohort baseline
UAE, age, male gender, diabetes mellitus, smoking, and low LDL
cholesterol were associated with incident microalbuminuria [23].
In general, these data are in line with our present findings obtained
in a cohort of community dwelling subjects with only few diabetic
patients included. Our data show that progressive albuminuria is
also observed in non-diabetic subjects, and that the factors
associated with progressive albuminuria in non-diabetics show
great overlap with those in diabetics. Interestingly, the impact of
Table 5. Score chart.
Score chart
Characteristic Points
Age (yrs)
,50 (reference) 0
50–70 1
.70 3
Gender
Male 4
Body mass index (kg/m2)
,18.5 0
18.5-25 (reference) 0
25-30 2
.30 3
Albuminuria (mg/24 h)
,15 (reference) 0
15-30 6
30-150 17
150-300 24
Total score Risk (%)
,16 0-5%
17-20 5–10%
21-23 10–20%
24-25 20–30%
26-27 30–40%
28-29 40–50%
30-31 –
32-33 60-70%
34 .70
doi:10.1371/journal.pone.0061119.t005
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having progressive albuminuria may also be comparable in non-
diabetic and diabetic subjects. In non-diabetic subjects progressive
albuminuria has also been shown to be associated with an
increased risk for cardiovascular morbidity and mortality
[11,12,24], and for the need for dialysis [11].
How could this score chart be implemented in clinical practice?
This chart suggests that if someone has a modestly elevated UAE,
even in absence of other renal risk factors, follow up of UAE may
be indicated. The impact of baseline albuminuria is very strong
when compared to the impact of the other predictors. The score
chart shows the relative impact of the various factors. The scoring
system will be of limited help in clinical assessment.
It is surprising that the predictive value of baseline UAE is that
important that blood pressure, plasma glucose and changes in
these covariates became only significant predictors of progressive
albuminuria after omitting baseline UAE from the multivariable
models. This finding can be of help for our understanding of the
interaction between blood pressure, glucose and UAE. Tradition-
ally, it was argued that elevated glucose and blood pressure are the
driving forces for a rise in UAE. This concept was however
challenged when it was shown in a population survey that the
prevalence of microalbuminuria in subjects not known to have
diabetes or hypertension is relatively high, being 6.6% [25]. In
comparison, microalbuminuria was found in 11.5% of those
known with hypertension, and in 16.4% of those known with
diabetes [25]. Since in the general population there are far more
subjects without diabetes mellitus or hypertension, than there are
subjects with diabetes mellitus or hypertension, this implied that in
the majority of microalbuminuric subjects microalbuminuria was
not due to these risk factors [25]. In line with this observation, it
was later shown that microalbuminuria is frequent not the result of
diabetes mellitus or hypertension, but that microalbuminuria may
also precede the onset of these risk factors [26–29]. Interestingly, it
has recently been hypothesized that at birth one is endowed with a
level of UAE, representing a vascular state that is determined
genetically or due to in-utero environmental factors, and that this
level of UAE may be associated with susceptibility to organ
damage [30,31]. This would explain why albuminuria is an
independent predictor of cardiovascular and renal outcome, and
new-onset hypertension and diabetes. Our present findings of a
predominant role of baseline UAE to predict progressive
albuminuria could be interpreted to support this hypothesis.
Our findings on risk prediction for progressive albuminuria are
in line with previous findings from the same cohort on risk
prediction for progressive renal function loss [8]. In both studies
we used a similar approach to define cases. In our study of
predictors of progressive renal function loss baseline eGFR was
also the most important predictor, in analogy of baseline
albuminuria predicting progressive albuminuria. In the prediction
model for eGFR loss, however, other factors, such as baseline
systolic blood pressure, UAE and C-reactive protein were also
significantly and strongly associated with risk, whereas in the
present prediction model for progressive albuminuria the relative
contribution of these risk factors is limited. Insights in the factors
that predict progression of albuminuria is the more relevant as a
rise in UAE has been shown to often precede a fall in eGFR,
especially in type 1 [32] and type 2 [33] diabetes mellitus. As
moreover, changes in eGFR in the range from normal to 60 ml/
min/1.73 m2 are relative difficult to detect, in these early cases
follow up of changes in UAE may be warranted to check for
progression in chronic kidney disease.
Our study has some limitations that need to be mentioned. First,
the data are limited to a Caucasian population, and thus the results
cannot directly be extrapolated to other ethnic groups. Second,
some variables under investigation were based on self-report,
which may have led to misclassification. In the present study,
however, questionnaire data were combined with objective data,
retrieved from pharmacy databases (medication use) or quantita-
tively measured (glucose and blood pressure). Third, as the intra-
individual level of UAE is subject to variation, e.g. due to physical
activity and inflammatory diseases, misclassification may have
been occurred. If this would be relevant, it will however only
strengthen our main conclusion since this is expected to lead to an
under- rather than overestimation of the significance of baseline
UAE as predictor of progressive albuminuria. Moreover, special
care was taken to assess UAE as precise as possible, for participants
Table 6. Diagnostic characteristics of the prediction model.
Total score Population (%) Identified events (%) Sensitivity (%) Specificity (%) PPV NPV
$30 0.3 (17) 9.8 (13) 9.8 99.9 76.5 98.0
$29 0.4 (23) 12.1 (16) 12.1 99.9 69.6 98.0
$28 0.5 (29) 12.1 (16) 12.1 99.9 55.2 98.0
$27 0.9 (52) 15.9 (21) 15.9 99.5 40.4 98.1
$26 1.4 (81) 22.0 (29) 22.0 99.1 35.8 98.2
$25 2.1 (121) 32.6 (43) 32.6 98.6 35.5 98.4
$24 4.4 (254) 50.0 (66) 50.0 96.7 26.0 98.8
$23 5.2 (300) 54.5 (72) 54.5 96.0 24.0 98.9
$22 5.9 (340) 59.8 (79) 59.8 95.4 23.2 99.1
$21 7.2 (415) 69.7 (92) 69.7 94.3 22.2 99.3
$20 8.0 (461) 73.5 (97) 73.5 93.6 21.0 99.3
$15 10.3 (593) 79.5 (105) 79.5 91.4 17.7 99.5
$10 18.0 (1037) 87.9 (116) 87.9 83.7 11.2 99.9
$5 48.1 (2772) 97.0 (128) 97.0 53.1 4.6 99.9
$0 100.0 (5762) 100.0 (132) 100.0 0.0 2.3 100.0
Abbreviations. PVV, positive predicting value; NPV, negative predicting value.
doi:10.1371/journal.pone.0061119.t006
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were advised not to collect urine in case of infectious diseases and
to refrain from intensive physical activity during the urine
collection period. Fourth, one should consider whether our
definition of progressive albuminuria is appropriate. We choose
a definition that combined a relative (belonging to the quintile of
subjects with highest percentage increase in UAE per year from
baseline to end of follow-up) AND an absolute criterion (UAE at
end of follow-up .150 mg/24 h) in analogy to the definition we
used to study a risk prediction model for progressive eGFR loss [8]
and in analogy to literature [4]. Importantly, our sensitivity
analyses using other criteria to define progressive albuminuria
showed essentially similar results. Fifth, the PREVEND cohort is
enriched for subjects with higher levels of UAE. We therefore
performed weighted analyses to adjust for this oversampling,
which rendered essentially similar results. Furthermore, because of
exclusion of participants without data on albuminuria at the
second screening round (and no data during follow-up), with
subsequently no possible calculation of progression in albuminuria,
any selection bias could have been possible. Furthermore, since
this study used internal validation, other studies are needed to test
external validity. Furthermore, ACEi/ARB use at baseline was
included as potential indicator of risk for progression of
albuminuria. We concluded that indeed the use of this medication
was associated with higher risk. This probably reflects bias by
indication, i.e. that subjects with a high chance for progressive
albuminuria were at baseline more likely to use this medication
that is known from literature to have a special favorable effect on
albuminuria. Finally, participants were censored in case they
started blood pressure, glucose and/or lipid lowering medication.
This was done because we wanted to study the natural course of
albuminuria and this medication is known to influence albumin-
uria (i.e. causing a decrease). Censoring these participants after the
second screening will not form a problem for our analyses, because
in these subjects follow-up albuminuria is available before start of
this medication. These subjects are therefore eligible to be defined
as having ‘‘progressive albuminuria’’. Only in subjects that started
such medication between the baseline and second screening this
medication there is no follow-up information on albuminuria
available. This indeed might be a source of bias.
What is the result when patients with CKD were excluded? In
our analyses we did not exclude subjects with a baseline UAE of
30–300 mg/24 h (N=566), as it has been shown that the cut-off
for microalbuminuria, that is .30 mg/24 h, is highly arbitrary.
The risk associated with albuminuria is continuous, with subjects
having UAE values as low as 10 mg/24 h already having a higher
risk than those with ,10 mg/24 h. When we exclude participants
with baseline CKD (defined as baseline eGFR ,60 mL/min/
1.73 m2 and/or baseline albuminuria. 30 mg/24 h) there are
only 16 subjects left that meet our definition of progression in
albuminuria for further analyses. This is not surprising as we
defined our endpoint not only as change in UAE, but also as that
final UAE should be at least 150 mg/24 h. This definition ensures
that the change in UAE is also clinically relevant. When limiting
the population to subjects with a baseline UAE value ,30 mg/
24 h, it will take them longer to reach the value .150 mg/24 h.
Consequently only a low number of subjects will have reached this
endpoint during the follow-up in our study. With a number of 16
‘‘cases’’ multivariable regression analyses are not possible.
Strengths of our study is that our data were obtained in a
relatively large scale epidemiological study in community dwelling
individuals with serial follow-up, that was specifically designed to
study the natural course of albuminuria. As such our data are not
post-hoc findings, but hypothesis driven. Data of four subsequent
screening rounds are available, with detailed objective information
on many covariates, including medication use. Furthermore,
albuminuria was assessed at each screening in two 24 h urine
samples, whereas in most epidemiological studies albuminuria is
assessed in one random spot sample, which is known to be subject
to more variability [34]. This makes the PREVEND cohort
uniquely suited to study the natural course of UAE and to
investigate risk factors for an increase in UAE in the general
population.
In conclusion, baseline albuminuria is by far the most important
variable that predicts risk of progressive albuminuria. It outweighs
other factors, such as age, male gender, body mass index, blood
pressure and glucose. Thus, in case screening programs are to be
designed to identify subjects at risk for progressive albuminuria
and associated morbidity and mortality, screening for albuminuria
is of more importance than screening for other cardiovascular risk
factors. Moreover, our data suggest that if someone has a modestly
elevated UAE, even in absence of other cardiovascular risk factors,
follow-up of albuminuria may be indicated.
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